Generate’s head of R&D returns to Merck Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 25 July, 2025

At Forge, better manufacturing isn’t a benchmark—it’s a mindset. Through innovative technologies and deep AAV expertise, we deliver end-to-end manufacturing services. Any stage. Any serotype. Built around your journey. sponsored by Forge Biologics

presented by Pur­pose, not just prod­uct: What sets Mirum apart

news CHMP recommends against Elevidys in Europe, in another blow to the gene therapy Memo Therapeutics says there’s still a path forward for kidney transplant drug that failed Phase 2 trial Generate's head of R&D returns to Merck; Galapagos shuffles leadership team

Aug 21 2:00pm ET Agentic AI is here: Real-world applications in life sciences & healthcare sponsored by IBM

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

ENDPOINTS PHARMA Sarepta's crisis week: How questions over patient deaths put the biotech's future in jeopardy •  Updated: Sarepta would have to conduct new studies to get back on market, FDA official says Two of biotech’s biggest champions in the House want to counter China's rise UnitedHealth says it's facing a DOJ investigation into its Medicare practices Vaccine maker Bavarian Nordic confirms it's in potential takeover talks

in case you missed it 1. Still in flux, Galapagos hires new execs, adjusts deal with Gilead, and considers selling its cell therapy business 2. Novartis inks deal with covalent medicines biotech Matchpoint for $60M upfront 3. Roche looks at direct-to-patient sales in the US, drops preclinical obesity drug from Carmot buy 4. Flagship’s two most-funded startups, Generate and Tessera, lay off employees 5. Rocket cuts 30% of staff as it plots path forward for gene therapies 6. AstraZeneca’s self-administered myasthenia gravis drug clears Phase 3 trial 7. TCG Labs Soleil gets another $400M for single-asset biotechs, expands to China 8. Australia-based life sciences VC firm nabs $287M for sixth fund 9. China's Sciwind is in talks to license weight-loss drug in US, CEO says 10.